{"url_path":"/sec/oncy/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000037-index.html","accession_number":"0001129928-26-000037","cik":"0001129928","ticker":"ONCY","issuer_name":"ONCOLYTICS BIOTECH INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000037-index.html","primary_entity_key":"0001129928","primary_entity_name":"ONCOLYTICS BIOTECH INC"},"word_count":85,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\nOn June 1, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing initial preclinical data for pelareorep in combination with RAS inhibitor modalities and plans for additional studies evaluating pelareorep in combination with multiple RAS-targeted agents. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section."}